Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2007 1
2008 1
2011 1
2012 1
2015 2
2016 1
2017 4
2018 5
2019 2
2020 2
2021 4
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, Shaw PJ, Staciuk R, Ifversen M, Pichler H, Vettenranta K, Svec P, Aleinikova O, Stein J, Güngör T, Toporski J, Truong TH, Diaz-de-Heredia C, Bierings M, Ariffin H, Essa M, Burkhardt B, Schultz K, Meisel R, Lankester A, Ansari M, Schrappe M; IBFM Study Group;; von Stackelberg A; IntReALL Study Group; Balduzzi A; I-BFM SCT Study Group; Corbacioglu S; EBMT Paediatric Diseases Working Party; Bader P. Peters C, et al. Among authors: poetschger u. J Clin Oncol. 2021 Feb 1;39(4):295-307. doi: 10.1200/JCO.20.02529. Epub 2020 Dec 17. J Clin Oncol. 2021. PMID: 33332189 Free PMC article. Clinical Trial.
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.
Flaadt T, Ladenstein RL, Ebinger M, Lode HN, Arnardóttir HB, Poetschger U, Schwinger W, Meisel R, Schuster FR, Döring M, Ambros PF, Queudeville M, Fuchs J, Warmann SW, Schäfer J, Seitz C, Schlegel P, Brecht IB, Holzer U, Feuchtinger T, Simon T, Schulte JH, Eggert A, Teltschik HM, Illhardt T, Handgretinger R, Lang P. Flaadt T, et al. Among authors: poetschger u. J Clin Oncol. 2023 Jun 10;41(17):3135-3148. doi: 10.1200/JCO.22.01630. Epub 2023 Feb 28. J Clin Oncol. 2023. PMID: 36854071 Free PMC article. Clinical Trial.
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study.
Garaventa A, Poetschger U, Valteau-Couanet D, Luksch R, Castel V, Elliott M, Ash S, Chan GCF, Laureys G, Beck-Popovic M, Vettenranta K, Balwierz W, Schroeder H, Owens C, Cesen M, Papadakis V, Trahair T, Schleiermacher G, Ambros P, Sorrentino S, Pearson ADJ, Ladenstein RL. Garaventa A, et al. Among authors: poetschger u. J Clin Oncol. 2021 Aug 10;39(23):2552-2563. doi: 10.1200/JCO.20.03144. Epub 2021 Jun 21. J Clin Oncol. 2021. PMID: 34152804 Clinical Trial.
Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials.
Wieczorek A, Manzitti C, Garaventa A, Gray J, Papadakis V, Valteau-Couanet D, Zachwieja K, Poetschger U, Pribill I, Fiedler S, Ladenstein R, Lode HN. Wieczorek A, et al. Among authors: poetschger u. Cancers (Basel). 2022 Apr 10;14(8):1919. doi: 10.3390/cancers14081919. Cancers (Basel). 2022. PMID: 35454826 Free PMC article.
Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial.
Eichinger A, Poetschger U, Glogova E, Bader P, Basu O, Beier R, Burkhardt B, Classen CF, Claviez A, Corbacioglu S, Deubzer HE, Greil J, Gruhn B, Güngör T, Kafa K, Kühl JS, Lang P, Lange BS, Meisel R, Müller I, Sauer MG, Schlegel PG, Schulz A, Stachel D, Strahm B, Wawer A, Peters C, Albert MH. Eichinger A, et al. Among authors: poetschger u. Leukemia. 2022 Nov;36(11):2567-2576. doi: 10.1038/s41375-022-01693-z. Epub 2022 Sep 12. Leukemia. 2022. PMID: 36097283 Free PMC article.
Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial.
Kuhlen M, Willasch AM, Dalle JH, Wachowiak J, Yaniv I, Ifversen M, Sedlacek P, Guengoer T, Lang P, Bader P, Sufliarska S, Balduzzi A, Strahm B, von Luettichau I, Hoell JI, Borkhardt A, Klingebiel T, Schrappe M, von Stackelberg A, Glogova E, Poetschger U, Meisel R, Peters C. Kuhlen M, et al. Among authors: poetschger u. Br J Haematol. 2018 Jan;180(1):82-89. doi: 10.1111/bjh.14965. Epub 2017 Nov 28. Br J Haematol. 2018. PMID: 29193007 Free article. Clinical Trial.
The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG.
Dalle JH, Balduzzi A, Bader P, Pieczonka A, Yaniv I, Lankester A, Bierings M, Yesilipek A, Sedlacek P, Ifversen M, Svec P, Toporski J, Gungor T, Wachowiak J, Glogova E, Poetschger U, Peters C. Dalle JH, et al. Among authors: poetschger u. Bone Marrow Transplant. 2021 Jan;56(1):257-266. doi: 10.1038/s41409-020-01014-x. Epub 2020 Aug 4. Bone Marrow Transplant. 2021. PMID: 32753706 Free PMC article.
Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high-risk or relapsed ALL - results of the ALL-SCT 2003 trial.
Kuhlen M, Bader P, Sauer M, Albert MH, Gruhn B, Güngör T, Kropshofer G, Lang P, Lawitschka A, Metzler M, Pentek F, Rossig C, Schlegel PG, Schrappe M, Schrum J, Schulz A, Schwinger W, von Stackelberg A, Strahm B, Suttorp M, Luettichau IT, Wößmann W, Borkhardt A, Meisel R, Poetschger U, Glogova E, Peters C. Kuhlen M, et al. Among authors: poetschger u. Br J Haematol. 2018 Oct;183(1):104-109. doi: 10.1111/bjh.15511. Epub 2018 Jul 20. Br J Haematol. 2018. PMID: 30028016 Free article.
22 results